力生制药(002393.SZ)：氯化钾缓释片通过上市许可申请

Core Viewpoint - The company, Lifesun Pharmaceutical, has received drug registration certificates from the National Medical Products Administration for its potassium chloride sustained-release tablets in 0.5g and 0.6g specifications, indicating successful approval for market entry [1]. Group 1 - The potassium chloride sustained-release tablets are indicated for the treatment and prevention of hypokalemia with or without metabolic alkalosis [1]. - These tablets are particularly useful for patients who do not respond well to dietary management with potassium-rich foods or reduced diuretic dosage [1].